Bank of America
KAPA

Bank of America’s Kairos Pharma KAPA Stock Holding History

Bank of America’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-134
Closed -$95 – 7077
2025
Q4 		$95 Sell
134
-170
-56% -$159 ﹤0.01% 6832
2025
Q3 		$356 Buy
304
+253
+496% +$289 ﹤0.01% 7642
2025
Q2 		$36 Buy
51
+30
+143% +$22 ﹤0.01% 8165
2025
Q1 		$20 Buy
21
+8
+62% +$10 ﹤0.01% 8140
2024
Q4 		$20 Buy
+13
New +$20 ﹤0.01% 8027

Other funds holding KAPA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $640M AUM 27.29% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America's KAPA Position: Q1 2026 in Review

Bank of America sold out of Kairos Pharma (KAPA) in Q1 2026, closing a stake of 134 shares — an estimated $95 sold.

Bank of America first reported a position in KAPA in Q4 2024 and held it in 5 quarters. The position peaked at $356 in Q3 2025. 11 funds tracked by Wall St. Rank hold KAPA as of Q1 2026.

  • Bank of America reported no remaining Kairos Pharma position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 134 Kairos Pharma shares in Q1 2026, an estimated $95.
  • Bank of America first reported a position in Kairos Pharma in Q4 2024 and held it in 5 quarters.
  • Bank of America's Kairos Pharma position peaked at $356 in Q3 2025.
  • 11 funds tracked by Wall St. Rank held Kairos Pharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.